Article(id=1329869606111523703, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329869572141855203, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2023.02.014, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1666886400000, receivedDateStr=2022-10-28, revisedDate=1676131200000, revisedDateStr=2023-02-12, acceptedDate=null, acceptedDateStr=null, onlineDate=1794995221878, onlineDateStr=2026-11-18, pubDate=1675958400000, pubDateStr=2023-02-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794995221878, onlineIssueDateStr=2026-11-18, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794995221878, creator=13701087609, updateTime=1794995221878, updator=13701087609, issue=Issue{id=1329869572141855203, tenantId=1146029695717560320, journalId=1319690329412173987, year='2023', volume='44', issue='2', pageStart='105', pageEnd='196', issueExtLink='null', onlineDate='null', pubDate='1675958400000', pubDateStr='2023-02-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794995213780, creator='13701087609', updateTime=1794995798529, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329872025146995085, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329869572141855203, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329872025146995086, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329869572141855203, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=186, endPage=192, ext={EN=ArticleExt(id=1329869606346404728, articleId=1329869606111523703, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Research progress on influencing factors of glucagon-like peptide-1 receptor agonists on blood glucose response and tolerance in diabetes mellitus type 2, columnId=1325221194584162830, journalTitle=World Clinical Drug, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

Glucagon-like peptide-1 receptor agonist (GLP-1RA) is an important hypoglycemic agent, which has various metabolic effects. It plays an important role in reducing body mass and treating complications of diabetes mellitus type 2 (T2DM). In terms of efficacy, GLP-1RA had a proportion of adverse responses, including baseline glycosylated hemoglobin, islet beta cell function, GLP-1RA drug dose, body mass index, ethnicity or predictable partial glycaemia response. In terms of tolerance, most GLP-1RA tolerance was negatively correlated with the course of treatment. The comprehensive management of T2DM requires patient-centered individualized treatment. This paper summarized the baseline characteristics related to glucose response and tolerance in the treatment of T2DM by GLP-1RA, and explored the appropriate population characteristics for GLP-1RA, in order to provide some reference for clinical medication.

, authors=Xiaolin WANG, Hao LU*, authorsList=Xiaolin WANG, Hao LU, authorCompany=null, correspAuthors=Hao LU, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329869606585480057, articleId=1329869606111523703, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=胰高血糖素样肽-1受体激动剂对2型糖尿病血糖应答及耐受性影响因素研究进展, columnId=1325221194743546384, journalTitle=世界临床药物, columnName=综述评论, runingTitle=null, highlight=null, articleAbstract=

胰高血糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonist,GLP-1RA)是目前重要的降糖药物,具有多种代谢效应,在减轻体质量和2型糖尿病(diabetes mellitus type 2,T2DM)并发症治疗方面亦有重要影响。疗效方面,GLP-1RA存在一定比例应答不良,包括基线糖化血红蛋白、胰岛β细胞功能、GLP-1RA药物剂量、体质量指数、种族或可预测部分GLP-1RA血糖应答;耐受性方面,多数GLP-1RA耐受性与疗程呈负相关。T2DM的综合管理需以患者为中心进行个体化治疗。现总结GLP-1RA治疗T2DM血糖应答及耐受性相关基线特征,探寻使用GLP-1RA的适宜人群特征,旨在为临床用药提供一定参考。

, authors=王晓琳, 陆灏*, authorsList=王晓琳, 陆灏, authorCompany=null, correspAuthors=陆灏, authorNote=

王晓琳,主治医师,研究方向:中医药治疗糖尿病临床与实验研究。

, correspAuthorsNote=
陆灏,主任医师,博士研究生导师,研究方向:中医药治疗糖尿病临床与实验研究。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=U6ZFyYiSzlBcnChMNNpj2Q==, magXml=0FRHPd5yWboOLngagdBtJg==, pdfUrl=null, pdf=TnL68DFRgLkfCxaLEk5jLw==, pdfFileSize=1582889, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=aizpQRPZFcR4jdcL9srZaA==, mapNumber=null, fund=null)}, authors=[Author(id=1329869606921024382, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869607009104768, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, authorId=1329869606921024382, language=EN, stringName=Xiaolin WANG, firstName=Xiaolin, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Endocrinology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869607084602241, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, authorId=1329869606921024382, language=CN, stringName=王晓琳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=上海中医药大学附属曙光医院内分泌科,上海 201203, bio={"content":"

王晓琳,主治医师,研究方向:中医药治疗糖尿病临床与实验研究。

"}, bioImg=null, bioContent=

王晓琳,主治医师,研究方向:中医药治疗糖尿病临床与实验研究。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869606811972474, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, xref=null, ext=[AuthorCompanyExt(id=1329869606832943995, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, companyId=1329869606811972474, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Endocrinology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China), AuthorCompanyExt(id=1329869606845526908, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, companyId=1329869606811972474, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海中医药大学附属曙光医院内分泌科,上海 201203)])]), Author(id=1329869607155905411, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329869607264957317, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, authorId=1329869607155905411, language=EN, stringName=Hao LU, firstName=Hao, middleName=null, lastName=LU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Department of Endocrinology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869607403369350, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, authorId=1329869607155905411, language=CN, stringName=陆灏, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=上海中医药大学附属曙光医院内分泌科,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869606811972474, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, xref=null, ext=[AuthorCompanyExt(id=1329869606832943995, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, companyId=1329869606811972474, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Endocrinology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China), AuthorCompanyExt(id=1329869606845526908, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, companyId=1329869606811972474, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海中医药大学附属曙光医院内分泌科,上海 201203)])])], keywords=[Keyword(id=1329869607533392775, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, language=EN, orderNo=1, keyword=glucagon-like peptide-1 receptor agonist), Keyword(id=1329869607596307336, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, language=EN, orderNo=2, keyword=blood glucose response), Keyword(id=1329869607667610505, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, language=EN, orderNo=3, keyword=tolerance), Keyword(id=1329869607730525066, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, language=EN, orderNo=4, keyword=clinical effect), Keyword(id=1329869607797633931, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, language=CN, orderNo=1, keyword=胰高血糖素样肽-1受体激动剂), Keyword(id=1329869607868937100, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, language=CN, orderNo=2, keyword=血糖应答), Keyword(id=1329869607948628877, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, language=CN, orderNo=3, keyword=耐受性), Keyword(id=1329869608003154830, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, language=CN, orderNo=4, keyword=临床疗效)], refs=[Reference(id=1329869608523248532, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Diabetes Federation. China Diabetes report 2000—2045[R]. (2021-11-08) [2022-08-15]. https://diabetesatlas.org/data/en/country/42/cn.html., articleTitle=null, refAbstract=null), Reference(id=1329869608602940309, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=徐斯盛, 华小懿, 肖兰, 等. 新型长效胰高血糖素样肽-1受体激动药——杜拉鲁肽[J]. 中国药房, 2015, 26(32): 4593-4595., articleTitle=null, refAbstract=null), Reference(id=1329869608732963734, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Tong J, D'Alessio D. Give the receptor a brake: slowing gastric emptying by GLP-1[J]. Diabetes, 2014, 63(2): 407-409., articleTitle=null, refAbstract=null), Reference(id=1329869608842015639, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=American Diabetes Association Professional Practice Committee. Cardiovascular disease and risk management: standards of medical care in diabetes - 2022[J]. Diabetes Care, 2022, 45(Suppl 1): S144-S174., articleTitle=null, refAbstract=null), Reference(id=1329869608967844760, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=葛均波, 霍勇, 高秀芳, 等. 改善心血管和肾脏结局的新型抗高血糖药物临床应用中国专家建议[J]. 中国循环杂志, 2020, 35(3): 231-238., articleTitle=null, refAbstract=null), Reference(id=1329869609051730841, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Morieri ML, Rigato M, Frison V, et al. Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies[J]. Metabolism, 2020, 106: 154190., articleTitle=null, refAbstract=null), Reference(id=1329869609127228314, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Wysham C, Wysham C, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)[J]. Diabetes Care, 2015, 38(7): 1393-1394., articleTitle=null, refAbstract=null), Reference(id=1329869609211114395, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Anderson SL, Trujillo JM, McDermott M, et al. Determining predictors of response to exenatide in type 2 diabetes[J]. J Am Pharm Assoc (2003), 2012, 52(4): 466-471., articleTitle=null, refAbstract=null), Reference(id=1329869609278223260, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Strain WD, Hope SV, Green A, et al. Type 2 diabetes mellitus in older people: a brief statement of key principles of modern day management including the assessment of frailty. A national collaborative stakeholder initiative[J]. Diabet Med, 2018, 35(7): 838-845., articleTitle=null, refAbstract=null), Reference(id=1329869609412440989, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=American Diabetes Association Professional Practice Committee. 6. Glycemic targets: standards of medical care in diabetes - 2022[J]. Diabetes Care, 2022, 45(Suppl 1): S83-S96., articleTitle=null, refAbstract=null), Reference(id=1329869609496327070, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Kyriakidou A, Koufakis T, Goulis DG, et al. Pharmacogenetics of the glucagon-like peptide-1 receptor agonist liraglutide: a step towards personalized type 2 diabetes management[J]. Curr Pharm Des, 2021, 27(8): 1025-1034., articleTitle=null, refAbstract=null), Reference(id=1329869609567630239, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Kyriakidou A, Kyriazou AV, Koufakis T, et al. Clinical and genetic predictors of glycemic control and weight loss response to liraglutide in patients with type 2 diabetes[J]. J Pers Med, 2022, 12(3): 424., articleTitle=null, refAbstract=null), Reference(id=1329869609638933408, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Imai K, Tsujimoto T, Goto A, et al. Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes[J]. Diabetol Metab Syndr, 2014, 6(1): 110., articleTitle=null, refAbstract=null), Reference(id=1329869609731208097, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Koufakis T, Papanas N, Papanas N, et al. Treatment options following metformin in primary prevention populations with type 2 diabetes: which is the right road to take?[J]. Expert Rev Clin Pharmacol, 2021, 14(10): 1189-1192., articleTitle=null, refAbstract=null), Reference(id=1329869609861231522, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Haraguchi A, Fujishima K, Ando T, et al. Multiple drug combination of anti-diabetic agents as a predictor for poor clinical response to liraglutide[J]. Minerva Endocrinol, 2014, 39(4): 289-297., articleTitle=null, refAbstract=null), Reference(id=1329869609936728995, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Nathan BM, Rudser KD, Abuzzahab MJ, et al. Predictors of weight-loss response with glucagon-like peptide-1 receptor agonist treatment among adolescents with severe obesity[J]. Clin Obes, 2016, 6(1): 73-78., articleTitle=null, refAbstract=null), Reference(id=1329869610003837860, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Shi Y, Liu S, Zhu J, et al. Efficacy and safety of once-weekly dulaglutide in adult Chinese patients with type 2 diabetes and lower baseline body mass index[J]. J Diabetes, 2021, 13(4): 353-357., articleTitle=null, refAbstract=null), Reference(id=1329869610075141029, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Kozawa J, Inoue K, Iwamoto R, et al. Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin-secreting capacity[J]. J Diabetes Investig, 2012, 3(3): 294-297., articleTitle=null, refAbstract=null), Reference(id=1329869610154832806, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Best JH, Hoogwerf BJ, Herman WH, et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database[J]. Diabetes Care, 2011, 34(1): 90-95., articleTitle=null, refAbstract=null), Reference(id=1329869610217747367, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Yang W, Chen L, Ji Q, et al. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial (*)[J]. Diabetes Obes Metab, 2011, 13(1): 81-88., articleTitle=null, refAbstract=null), Reference(id=1329869610289050536, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Aroda VR, Brett J, Khutoryansky N, et al. Identifying predictors of response to liraglutide in type 2 diabetes using recursive partitioning analysis[J]. Can J Diabetes, 2012, 36(5): S45., articleTitle=null, refAbstract=null), Reference(id=1329869610381325225, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Onishi Y, Oura T, Matsui A, et al. Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan[J]. Endocr J, 2017, 64(5): 553-560., articleTitle=null, refAbstract=null), Reference(id=1329869610456822698, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Aroda VR, Bauer R, Christiansen E, et al. Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme[J]. Diabetes Obes Metab, 2022, 24(7): 1338-1350., articleTitle=null, refAbstract=null), Reference(id=1329869610532320171, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Shin J, Chang JS, Kim HS, et al. Effects of a 6-month exenatide therapy on HbA1c and weight in Korean patients with type 2 diabetes: a retrospective cohort study[J]. Diabetes Metab J, 2012, 36(5): 364-370., articleTitle=null, refAbstract=null), Reference(id=1329869610603623340, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Babenko AY, Savitskaya DA, Kononova YA, et al. Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity[J]. J Diabetes Res, 2019, 2019: 1365162., articleTitle=null, refAbstract=null), Reference(id=1329869610674926509, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Yu M, Yuan GY, Zhang B, et al. Efficacy and safety of dulaglutide by baseline HbA1c in Chinese patients with type 2 diabetes: a post hoc analysis[J]. Diabetes Ther, 2020, 11(5): 1147-1159., articleTitle=null, refAbstract=null), Reference(id=1329869610742035374, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Khan M, Ouyang J, Perkins K, et al. Determining predictors of early response to exenatide in patients with type 2 diabetes mellitus[J]. J Diabetes Res, 2015, 2015: 162718., articleTitle=null, refAbstract=null), Reference(id=1329869610796561327, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Jones AG, McDonald TJ, Shields BM, et al. Markers of β-cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes[J]. Diabetes Care, 2016, 39(2): 250-257., articleTitle=null, refAbstract=null), Reference(id=1329869610867864496, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Rowlands J, Heng J, Newsholme P, et al. Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function[J]. Front Endocrinol (Lausanne), 2018, 9: 672., articleTitle=null, refAbstract=null), Reference(id=1329869610947556273, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=Kawasaki H, Springett GM, Mochizuki N, et al. A family of cAMP-binding proteins that directly activate Rap1[J]. Science, 1998, 282(5397): 2275-2279., articleTitle=null, refAbstract=null), Reference(id=1329869611010470834, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Sugawara K, Shibasaki T, Takahashi H, et al. Structure and functional roles of Epac2 (Rapgef4)[J]. Gene, 2016, 575(2 Pt 3): 577-583., articleTitle=null, refAbstract=null), Reference(id=1329869611106939827, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Hernández C, Gómez-Peralta F, Simó-Servat O, et al. Usefulness of circulating EPAC1 as biomarkers of therapeutic response to GLP-1 receptor agonists[J]. Acta Diabetol, 2022, 59(11): 1437-1442., articleTitle=null, refAbstract=null), Reference(id=1329869611178242996, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=Lin CH, Lee YS, Huang YY, et al. Polymorphisms of GLP-1 receptor gene and response to GLP-1 analogue in patients with poorly controlled type 2 diabetes[J]. J Diabetes Res, 2015, 2015: 176949., articleTitle=null, refAbstract=null), Reference(id=1329869611266323381, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=Yu M, Wang K, Liu H, et al. GLP1R variant is associated with response to exenatide in overweight Chinese type 2 diabetes patients[J]. Pharmacogenomics, 2019, 20(4): 273-277., articleTitle=null, refAbstract=null), Reference(id=1329869611362792374, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=Beinborn M, Worrall CI, McBride EW, et al. A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness[J]. Regul Pept, 2005, 130(1-2): 1-6., articleTitle=null, refAbstract=null), Reference(id=1329869611438289847, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=Guan Z, Du Y, Li R, et al. Association between glucagon-like peptide-1 receptor gene polymorphism and treatment response to GLP1R agonists in Chinese patients with type 2 diabetes: a prospective cohort study[J]. Eur J Clin Pharmacol, 2022, 78(5): 793-799., articleTitle=null, refAbstract=null), Reference(id=1329869611526370232, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=Kwak SH, Chae J, Lee S, et al. Nonsynonymous variants in PAX4 and GLP1R are associated with type 2 diabetes in an East Asian population[J]. Diabetes, 2018, 67(9): 1892-1902., articleTitle=null, refAbstract=null), Reference(id=1329869611597673401, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=Jensterle M, Pirš B, Goričar K, et al. Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study[J]. Eur J Clin Pharmacol, 71(7): 817-824., articleTitle=null, refAbstract=null), Reference(id=1329869611685753786, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=Hart LM, Fritsche A, Nijpels G, et al. The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway[J]. Diabetes, 2013, 62(9): 3275-3281., articleTitle=null, refAbstract=null), Reference(id=1329869611765445563, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=Chedid V, Vijayvargiya P, Carlson P, et al. Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: a pilot pharmacogenetics study[J]. Neurogastroenterol Motil, 2018, 30(7): e13313., articleTitle=null, refAbstract=null), Reference(id=1329869611836748732, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=Lingvay I, Catarig AM, Frias JP, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial[J]. Lancet Diabetes Endocrinol, 2019, 7(11): 834-844., articleTitle=null, refAbstract=null), Reference(id=1329869611903857597, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2016, 375(4): 311-322., articleTitle=null, refAbstract=null), Reference(id=1329869611983549374, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=Macconell L, Brown C, Gurney K, et al. Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5 594 patients from 19 placebo-controlled and comparator-controlled clinical trials[J]. Diabetes Metab Syndr Obes, 2012, 5: 29-41., articleTitle=null, refAbstract=null), Reference(id=1329869612063241151, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=Yoo JH, Cho YK, Lee J, et al. Clinical efficacy and parameters affecting the response to dulaglutide treatment in patients with type 2 diabetes: a retrospective, real-world data study[J]. Diabetes Ther, 2019, 10(4): 1453-1463., articleTitle=null, refAbstract=null), Reference(id=1329869612147127232, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=Frias JP, Wynne AG, Matyjaszek-Matuszek B, et al. Efficacy and safety of an expanded dulaglutide dose range: a phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin[J]. Diabetes Obes Metab, 2019, 21(9): 2048-2057., articleTitle=null, refAbstract=null), Reference(id=1329869612214236097, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=Yau AMW, McLaughlin J, McLaughlin J, et al. A pilot study investigating the influence of glucagon-like peptide-1 receptor single nucleotide polymorphisms on gastric emptying rate in Caucasian men[J]. Front Physiol, 2018, 9: 1331., articleTitle=null, refAbstract=null)], funds=[Fund(id=1329869608087040911, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, awardId=82074381; 81874434, language=CN, fundingSource=国家自然科学基金(82074381; 81874434), fundOrder=null, country=null), Fund(id=1329869608149955472, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, awardId=ZY(2021-2023)-0302, language=CN, fundingSource=长三角中医内分泌代谢病专科联盟(ZY(2021-2023)-0302), fundOrder=null, country=null), Fund(id=1329869608212870033, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, awardId=21S21900700, language=CN, fundingSource=上海市科委科研计划项目(21S21900700), fundOrder=null, country=null), Fund(id=1329869608288367506, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, awardId=shslczdzk05401, language=CN, fundingSource=上海市临床重点专科(shslczdzk05401), fundOrder=null, country=null), Fund(id=1329869608384836499, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, awardId=20DZ2272200, language=CN, fundingSource=上海市中医临床重点实验室(20DZ2272200), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1329869606811972474, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, xref=null, ext=[AuthorCompanyExt(id=1329869606832943995, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, companyId=1329869606811972474, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Endocrinology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China), AuthorCompanyExt(id=1329869606845526908, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, companyId=1329869606811972474, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海中医药大学附属曙光医院内分泌科,上海 201203)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2023.02.014, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.02.014, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2023.02.014, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2023.02.014, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1675958400000, fullTextJson=null, articleText=null, reference=null)
收藏切换
胰高血糖素样肽-1受体激动剂对2型糖尿病血糖应答及耐受性影响因素研究进展
王晓琳 , 陆灏 *
世界临床药物 | 综述评论 2023,44(2): 186-192
收起
收藏切换
世界临床药物 |综述评论 2023 , 44 (2) : 186 -192
胰高血糖素样肽-1受体激动剂对2型糖尿病血糖应答及耐受性影响因素研究进展
全屏
[Author(id=1329869606921024382, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869607009104768, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, authorId=1329869606921024382, language=EN, stringName=Xiaolin WANG, firstName=Xiaolin, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Endocrinology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869607084602241, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, authorId=1329869606921024382, language=CN, stringName=王晓琳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=上海中医药大学附属曙光医院内分泌科,上海 201203, bio={"content":"

王晓琳,主治医师,研究方向:中医药治疗糖尿病临床与实验研究。

"}, bioImg=null, bioContent=

王晓琳,主治医师,研究方向:中医药治疗糖尿病临床与实验研究。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869606811972474, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, xref=null, ext=[AuthorCompanyExt(id=1329869606832943995, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, companyId=1329869606811972474, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Endocrinology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China), AuthorCompanyExt(id=1329869606845526908, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, companyId=1329869606811972474, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海中医药大学附属曙光医院内分泌科,上海 201203)])]), Author(id=1329869607155905411, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329869607264957317, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, authorId=1329869607155905411, language=EN, stringName=Hao LU, firstName=Hao, middleName=null, lastName=LU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Department of Endocrinology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869607403369350, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, authorId=1329869607155905411, language=CN, stringName=陆灏, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=上海中医药大学附属曙光医院内分泌科,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869606811972474, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, xref=null, ext=[AuthorCompanyExt(id=1329869606832943995, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, companyId=1329869606811972474, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Endocrinology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China), AuthorCompanyExt(id=1329869606845526908, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869606111523703, companyId=1329869606811972474, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海中医药大学附属曙光医院内分泌科,上海 201203)])])]
王晓琳, 陆灏*
作者信息
  • 上海中医药大学附属曙光医院内分泌科,上海 201203
通讯作者:
陆灏,主任医师,博士研究生导师,研究方向:中医药治疗糖尿病临床与实验研究。
作者简介:

王晓琳,主治医师,研究方向:中医药治疗糖尿病临床与实验研究。

Research progress on influencing factors of glucagon-like peptide-1 receptor agonists on blood glucose response and tolerance in diabetes mellitus type 2
Xiaolin WANG, Hao LU*
Affiliations
  • Department of Endocrinology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
出版时间: 2023-02-10 doi: 10.13683/j.wph.2023.02.014
文章导航
收藏切换

胰高血糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonist,GLP-1RA)是目前重要的降糖药物,具有多种代谢效应,在减轻体质量和2型糖尿病(diabetes mellitus type 2,T2DM)并发症治疗方面亦有重要影响。疗效方面,GLP-1RA存在一定比例应答不良,包括基线糖化血红蛋白、胰岛β细胞功能、GLP-1RA药物剂量、体质量指数、种族或可预测部分GLP-1RA血糖应答;耐受性方面,多数GLP-1RA耐受性与疗程呈负相关。T2DM的综合管理需以患者为中心进行个体化治疗。现总结GLP-1RA治疗T2DM血糖应答及耐受性相关基线特征,探寻使用GLP-1RA的适宜人群特征,旨在为临床用药提供一定参考。

胰高血糖素样肽-1受体激动剂  /  血糖应答  /  耐受性  /  临床疗效

Glucagon-like peptide-1 receptor agonist (GLP-1RA) is an important hypoglycemic agent, which has various metabolic effects. It plays an important role in reducing body mass and treating complications of diabetes mellitus type 2 (T2DM). In terms of efficacy, GLP-1RA had a proportion of adverse responses, including baseline glycosylated hemoglobin, islet beta cell function, GLP-1RA drug dose, body mass index, ethnicity or predictable partial glycaemia response. In terms of tolerance, most GLP-1RA tolerance was negatively correlated with the course of treatment. The comprehensive management of T2DM requires patient-centered individualized treatment. This paper summarized the baseline characteristics related to glucose response and tolerance in the treatment of T2DM by GLP-1RA, and explored the appropriate population characteristics for GLP-1RA, in order to provide some reference for clinical medication.

glucagon-like peptide-1 receptor agonist  /  blood glucose response  /  tolerance  /  clinical effect
王晓琳, 陆灏. 胰高血糖素样肽-1受体激动剂对2型糖尿病血糖应答及耐受性影响因素研究进展. 世界临床药物, 2023 , 44 (2) : 186 -192 . DOI: 10.13683/j.wph.2023.02.014
Xiaolin WANG, Hao LU. Research progress on influencing factors of glucagon-like peptide-1 receptor agonists on blood glucose response and tolerance in diabetes mellitus type 2[J]. World Clinical Drug, 2023 , 44 (2) : 186 -192 . DOI: 10.13683/j.wph.2023.02.014
  • 国家自然科学基金(82074381; 81874434)
  • 长三角中医内分泌代谢病专科联盟(ZY(2021-2023)-0302)
  • 上海市科委科研计划项目(21S21900700)
  • 上海市临床重点专科(shslczdzk05401)
  • 上海市中医临床重点实验室(20DZ2272200)
参考文献 引证文献
排序方式:
[1]
Diabetes Federation. China Diabetes report 2000—2045[R]. (2021-11-08) [2022-08-15]. https://diabetesatlas.org/data/en/country/42/cn.html.
[2]
徐斯盛, 华小懿, 肖兰, 等. 新型长效胰高血糖素样肽-1受体激动药——杜拉鲁肽[J]. 中国药房, 2015, 26(32): 4593-4595.
[3]
Tong J, D'Alessio D. Give the receptor a brake: slowing gastric emptying by GLP-1[J]. Diabetes, 2014, 63(2): 407-409.
[4]
American Diabetes Association Professional Practice Committee. Cardiovascular disease and risk management: standards of medical care in diabetes - 2022[J]. Diabetes Care, 2022, 45(Suppl 1): S144-S174.
[5]
葛均波, 霍勇, 高秀芳, 等. 改善心血管和肾脏结局的新型抗高血糖药物临床应用中国专家建议[J]. 中国循环杂志, 2020, 35(3): 231-238.
[6]
Morieri ML, Rigato M, Frison V, et al. Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies[J]. Metabolism, 2020, 106: 154190.
[7]
Wysham C, Wysham C, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)[J]. Diabetes Care, 2015, 38(7): 1393-1394.
[8]
Anderson SL, Trujillo JM, McDermott M, et al. Determining predictors of response to exenatide in type 2 diabetes[J]. J Am Pharm Assoc (2003), 2012, 52(4): 466-471.
[9]
Strain WD, Hope SV, Green A, et al. Type 2 diabetes mellitus in older people: a brief statement of key principles of modern day management including the assessment of frailty. A national collaborative stakeholder initiative[J]. Diabet Med, 2018, 35(7): 838-845.
[10]
American Diabetes Association Professional Practice Committee. 6. Glycemic targets: standards of medical care in diabetes - 2022[J]. Diabetes Care, 2022, 45(Suppl 1): S83-S96.
[11]
Kyriakidou A, Koufakis T, Goulis DG, et al. Pharmacogenetics of the glucagon-like peptide-1 receptor agonist liraglutide: a step towards personalized type 2 diabetes management[J]. Curr Pharm Des, 2021, 27(8): 1025-1034.
[12]
Kyriakidou A, Kyriazou AV, Koufakis T, et al. Clinical and genetic predictors of glycemic control and weight loss response to liraglutide in patients with type 2 diabetes[J]. J Pers Med, 2022, 12(3): 424.
[13]
Imai K, Tsujimoto T, Goto A, et al. Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes[J]. Diabetol Metab Syndr, 2014, 6(1): 110.
[14]
Koufakis T, Papanas N, Papanas N, et al. Treatment options following metformin in primary prevention populations with type 2 diabetes: which is the right road to take?[J]. Expert Rev Clin Pharmacol, 2021, 14(10): 1189-1192.
[15]
Haraguchi A, Fujishima K, Ando T, et al. Multiple drug combination of anti-diabetic agents as a predictor for poor clinical response to liraglutide[J]. Minerva Endocrinol, 2014, 39(4): 289-297.
[16]
Nathan BM, Rudser KD, Abuzzahab MJ, et al. Predictors of weight-loss response with glucagon-like peptide-1 receptor agonist treatment among adolescents with severe obesity[J]. Clin Obes, 2016, 6(1): 73-78.
[17]
Shi Y, Liu S, Zhu J, et al. Efficacy and safety of once-weekly dulaglutide in adult Chinese patients with type 2 diabetes and lower baseline body mass index[J]. J Diabetes, 2021, 13(4): 353-357.
[18]
Kozawa J, Inoue K, Iwamoto R, et al. Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin-secreting capacity[J]. J Diabetes Investig, 2012, 3(3): 294-297.
[19]
Best JH, Hoogwerf BJ, Herman WH, et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database[J]. Diabetes Care, 2011, 34(1): 90-95.
[20]
Yang W, Chen L, Ji Q, et al. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial (*)[J]. Diabetes Obes Metab, 2011, 13(1): 81-88.
[21]
Aroda VR, Brett J, Khutoryansky N, et al. Identifying predictors of response to liraglutide in type 2 diabetes using recursive partitioning analysis[J]. Can J Diabetes, 2012, 36(5): S45.
[22]
Onishi Y, Oura T, Matsui A, et al. Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan[J]. Endocr J, 2017, 64(5): 553-560.
[23]
Aroda VR, Bauer R, Christiansen E, et al. Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme[J]. Diabetes Obes Metab, 2022, 24(7): 1338-1350.
[24]
Shin J, Chang JS, Kim HS, et al. Effects of a 6-month exenatide therapy on HbA1c and weight in Korean patients with type 2 diabetes: a retrospective cohort study[J]. Diabetes Metab J, 2012, 36(5): 364-370.
[25]
Babenko AY, Savitskaya DA, Kononova YA, et al. Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity[J]. J Diabetes Res, 2019, 2019: 1365162.
[26]
Yu M, Yuan GY, Zhang B, et al. Efficacy and safety of dulaglutide by baseline HbA1c in Chinese patients with type 2 diabetes: a post hoc analysis[J]. Diabetes Ther, 2020, 11(5): 1147-1159.
[27]
Khan M, Ouyang J, Perkins K, et al. Determining predictors of early response to exenatide in patients with type 2 diabetes mellitus[J]. J Diabetes Res, 2015, 2015: 162718.
[28]
Jones AG, McDonald TJ, Shields BM, et al. Markers of β-cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes[J]. Diabetes Care, 2016, 39(2): 250-257.
[29]
Rowlands J, Heng J, Newsholme P, et al. Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function[J]. Front Endocrinol (Lausanne), 2018, 9: 672.
[30]
Kawasaki H, Springett GM, Mochizuki N, et al. A family of cAMP-binding proteins that directly activate Rap1[J]. Science, 1998, 282(5397): 2275-2279.
[31]
Sugawara K, Shibasaki T, Takahashi H, et al. Structure and functional roles of Epac2 (Rapgef4)[J]. Gene, 2016, 575(2 Pt 3): 577-583.
[32]
Hernández C, Gómez-Peralta F, Simó-Servat O, et al. Usefulness of circulating EPAC1 as biomarkers of therapeutic response to GLP-1 receptor agonists[J]. Acta Diabetol, 2022, 59(11): 1437-1442.
[33]
Lin CH, Lee YS, Huang YY, et al. Polymorphisms of GLP-1 receptor gene and response to GLP-1 analogue in patients with poorly controlled type 2 diabetes[J]. J Diabetes Res, 2015, 2015: 176949.
[34]
Yu M, Wang K, Liu H, et al. GLP1R variant is associated with response to exenatide in overweight Chinese type 2 diabetes patients[J]. Pharmacogenomics, 2019, 20(4): 273-277.
[35]
Beinborn M, Worrall CI, McBride EW, et al. A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness[J]. Regul Pept, 2005, 130(1-2): 1-6.
[36]
Guan Z, Du Y, Li R, et al. Association between glucagon-like peptide-1 receptor gene polymorphism and treatment response to GLP1R agonists in Chinese patients with type 2 diabetes: a prospective cohort study[J]. Eur J Clin Pharmacol, 2022, 78(5): 793-799.
[37]
Kwak SH, Chae J, Lee S, et al. Nonsynonymous variants in PAX4 and GLP1R are associated with type 2 diabetes in an East Asian population[J]. Diabetes, 2018, 67(9): 1892-1902.
[38]
Jensterle M, Pirš B, Goričar K, et al. Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study[J]. Eur J Clin Pharmacol, 71(7): 817-824.
[39]
Hart LM, Fritsche A, Nijpels G, et al. The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway[J]. Diabetes, 2013, 62(9): 3275-3281.
[40]
Chedid V, Vijayvargiya P, Carlson P, et al. Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: a pilot pharmacogenetics study[J]. Neurogastroenterol Motil, 2018, 30(7): e13313.
[41]
Lingvay I, Catarig AM, Frias JP, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial[J]. Lancet Diabetes Endocrinol, 2019, 7(11): 834-844.
[42]
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2016, 375(4): 311-322.
[43]
Macconell L, Brown C, Gurney K, et al. Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5 594 patients from 19 placebo-controlled and comparator-controlled clinical trials[J]. Diabetes Metab Syndr Obes, 2012, 5: 29-41.
[44]
Yoo JH, Cho YK, Lee J, et al. Clinical efficacy and parameters affecting the response to dulaglutide treatment in patients with type 2 diabetes: a retrospective, real-world data study[J]. Diabetes Ther, 2019, 10(4): 1453-1463.
[45]
Frias JP, Wynne AG, Matyjaszek-Matuszek B, et al. Efficacy and safety of an expanded dulaglutide dose range: a phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin[J]. Diabetes Obes Metab, 2019, 21(9): 2048-2057.
[46]
Yau AMW, McLaughlin J, McLaughlin J, et al. A pilot study investigating the influence of glucagon-like peptide-1 receptor single nucleotide polymorphisms on gastric emptying rate in Caucasian men[J]. Front Physiol, 2018, 9: 1331.
2023年第44卷第2期
12
3
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2023.02.014
  • 接收时间:2022-10-28
  • 首发时间:2026-11-18
  • 出版时间:2023-02-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2022-10-28
  • 修回日期:2023-02-12
基金
国家自然科学基金(82074381; 81874434)
长三角中医内分泌代谢病专科联盟(ZY(2021-2023)-0302)
上海市科委科研计划项目(21S21900700)
上海市临床重点专科(shslczdzk05401)
上海市中医临床重点实验室(20DZ2272200)
作者信息
    上海中医药大学附属曙光医院内分泌科,上海 201203

通讯作者:

陆灏,主任医师,博士研究生导师,研究方向:中医药治疗糖尿病临床与实验研究。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2023.02.014
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏